Telisotuzumab vedotin

Telisotuzumab Vedotin: Overview

Telisotuzumab Vedotin is an antineoplastic antibody-drug conjugate designed to target c-Met-overexpressing cancer cells. It combines a humanized monoclonal antibody with a microtubule-disrupting agent to deliver localized cytotoxic therapy to advanced tumors.

What Is Telisotuzumab Vedotin & How Does It Work?

Telisotuzumab Vedotin is a specialized Targeted Therapy known as an antibody-drug conjugate that acts like a guided missile against cancer cells. The Biologic antibody portion (telisotuzumab) specifically seeks out and attaches to c-Met, a protein receptor found in high amounts on the surface of certain lung cancer cells. Once attached, the cancer cell absorbs the medication inside itself. Enzymes within the cell then cut the linker chain, releasing the active payload called monomethyl auristatin E (MMAE). MMAE disrupts the internal structural skeleton (microtubules) of the cell, stopping it from dividing and triggering programmed cell death (apoptosis) while sparing healthy cells that lack high c-Met expression.

Is Telisotuzumab Vedotin FDA Approved?

Telisotuzumab Vedotin received official prescription approval from the United States Food and Drug Administration in May 2025 under the brand name Emrelis. In a specialized Gastroenterology and oncology care setting, medical specialists utilize Telisotuzumab Vedotin to manage advanced non-small cell lung cancer that has progressed despite prior systemic treatments.

What Is Telisotuzumab Vedotin Used For?

• Treatment of adult patients with locally advanced non-squamous non-small-cell lung cancer (NSCLC) exhibiting high c-Met protein overexpression.
• Treatment of metastatic non-squamous non-small-cell lung cancer in patients who have received prior systemic therapy.
• Palliative targeted management of refractory pulmonary malignancies identified via an FDA-approved diagnostic test.

Before Taking Telisotuzumab Vedotin: Contraindications & Precautions

Patients must undergo thorough diagnostic testing and physical screening before starting Telisotuzumab Vedotin. The cytotoxic payload requires strict monitoring of nerve and lung function.

Who Should Not Take Telisotuzumab Vedotin?

Telisotuzumab Vedotin is strictly contraindicated in patients with a history of severe, life-threatening hypersensitivity to Telisotuzumab Vedotin, monomethyl auristatin E (MMAE), or any formulation excipients. Patients with active, severe interstitial lung disease or uncontrolled peripheral neuropathy should avoid initiating therapy until clinically stabilized.

Telisotuzumab Vedotin: Pregnancy & Fertility

Telisotuzumab Vedotin can cause fetal harm when administered to a pregnant woman due to its cytotoxic microtubule-disrupting mechanism. Female patients of reproductive potential must use effective contraception during treatment and for several months following the final dose. Male patients with female partners of reproductive potential should also use effective contraception. Telisotuzumab Vedotin may impair male and female fertility parameters, which may be irreversible.

Tell Your Doctor Before Taking Telisotuzumab Vedotin

Inform your oncologist if you have a history of lung disease, interstitial lung disease, or radiation pneumonitis. Disclose any existing peripheral neuropathy, numbness, tingling, or weakness in your hands or feet. List all current prescription medications, strong CYP3A4 inhibitors or inducers, over-the-counter drugs, and herbal supplements.

Telisotuzumab Vedotin: Dosage & Administration

Telisotuzumab Vedotin is supplied as a lyophilized powder in single-dose vials that must be reconstituted and diluted by healthcare professionals for intravenous infusion.

• Intravenous Infusion: Administered slowly into a vein over a specified infusion time.
• Diagnostic Requirement: Presence of high c-Met protein overexpression must be confirmed by an FDA-approved test prior to initiating treatment.
• Dosing Adjustments: Doses may be delayed, reduced, or permanently discontinued based on individual safety and adverse reaction severity.

Standard Telisotuzumab Vedotin Dosing

The recommended dosage of Telisotuzumab Vedotin for adult patients with locally advanced or metastatic non-squamous NSCLC is based on total body weight, administered intravenously according to official prescribing guidelines. Treatment continues until disease progression or unacceptable toxicity occurs. Dose modifications are strictly implemented for patients experiencing grade 2 or higher peripheral neuropathy, pneumonitis, or severe neutropenia.

How Telisotuzumab Vedotin Is Administered

A healthcare provider reconstitutes the sterile lyophilized powder with sterile water for injection and dilutes it in an intravenous infusion bag. The solution is visually inspected for particulate matter and administered through an intravenous line equipped with a sterile, low-protein-binding filter.

Telisotuzumab Vedotin: Clinical Efficacy & Research

Established clinical consensus confirms that Telisotuzumab Vedotin provides clinically meaningful objective response rates and durable disease control in patients with c-Met-overexpressing non-squamous NSCLC. Multi-center clinical trials demonstrated that targeting c-Met overexpressing tumors with this antibody-drug conjugate successfully induced tumor shrinkage in patients whose disease progressed after prior chemotherapy and Immunotherapy. Research confirms that the targeted release of MMAE maximizes tumor cell cytotoxicity while limiting systemic exposure compared to traditional free chemotherapy agents.

Telisotuzumab Vedotin: Side Effects & Safety Profile

Telisotuzumab Vedotin carries specific adverse reaction risks linked to both its Biologic antibody component and its cytotoxic payload.

Common Telisotuzumab Vedotin Side Effects

• Numbness, tingling, or burning sensations in hands and feet (peripheral neuropathy)
• Fatigue, generalized weakness, and loss of appetite
• Nausea, mild diarrhea, or constipation
• Hypoalbuminemia, elevated liver enzymes, and mild musculoskeletal pain

Serious Telisotuzumab Adverse Events

• Severe or fatal interstitial lung disease (ILD) and pneumonitis
• Severe, progressive peripheral motor and sensory neuropathy
• Ocular toxicity, including keratitis, dry eye syndrome, and visual disturbances
• Severe neutropenia and serious opportunistic infections

Managing Telisotuzumab Vedotin Side Effects

If mild numbness or nausea occurs, inform your oncology care team during your routine visits. Stop receiving Telisotuzumab Vedotin and seek immediate emergency care if you experience new or worsening cough, shortness of breath, chest pain, or severe visual changes.

Telisotuzumab Vedotin: Interactions & What to Avoid

Co-administering Telisotuzumab Vedotin with strong hepatic enzyme modulators can alter the clearance of the released MMAE payload.

Telisotuzumab Vedotin: Interactions

• Strong CYP3A4 inhibitors (ketoconazole, itraconazole): Co-administration increases plasma exposure of the MMAE payload, heightening toxicity risks.
• Strong CYP3A4 inducers (rifampin, carbamazepine): Reduce MMAE systemic exposure, potentially decreasing antitumor efficacy.
• P-glycoprotein inhibitors: May alter the transport and clearance profile of the cytotoxic payload.

Telisotuzumab Vedotin: Food & Alcohol

Dietary intake does not directly interfere with intravenous infusions of Telisotuzumab Vedotin. However, patients should avoid grapefruit juice and related products, as they can inhibit CYP3A4 enzymes and alter payload elimination.

Telisotuzumab Vedotin: Missed Dose, Overdose & Storage

Because Telisotuzumab Vedotin is administered under medical supervision in a clinical oncology setting, strict administration protocols are maintained.

Missed Dose of Telisotuzumab Vedotin

If an infusion appointment for Telisotuzumab Vedotin is missed, contact your oncology clinic immediately to reschedule your treatment. Do not wait for the next scheduled cycle without consulting your care team.

Telisotuzumab Vedotin: Overdose & Emergency

Overdosage of Telisotuzumab Vedotin increases the risk and severity of peripheral neuropathy, severe bone marrow suppression, and pneumonitis. In the event of an accidental overdose, supportive care and close monitoring of vital signs and blood counts are initiated immediately.

How To Store Telisotuzumab Vedotin

Store unopened Telisotuzumab Vedotin vials in a refrigerator between 2°C and 8°C (36°F and 46°F) in their original carton to protect from light. Reconstituted and diluted solutions should be administered immediately or stored under refrigerated conditions according to package instructions.

Telisotuzumab Vedotin: Patient Management & Monitoring

Rigorous baseline screening and ongoing clinical laboratory testing ensure safe administration of Telisotuzumab Vedotin.

Tests Before Starting Telisotuzumab Vedotin

• FDA-approved tissue biomarker test to confirm high c-Met protein overexpression in tumor samples.
• Baseline pulmonary evaluation, neurological assessment for neuropathy, and complete blood count (CBC) with liver function panels.

Monitoring During Telisotuzumab Vedotin Treatment

• Continuous monitoring for new or worsening respiratory symptoms, such as dyspnea, cough, or fever.
• Regular neurological examinations for signs of sensory or motor peripheral neuropathy before each dose.

Telisotuzumab Vedotin: Do’s and Don’ts

• Do inform your doctor immediately if you develop any vision changes or eye irritation.
• Do use effective birth control during treatment and for the recommended period after the last dose.
• Don’t receive live vaccines while undergoing active treatment with Telisotuzumab Vedotin.
• Don’t drive or operate heavy machinery if you experience severe fatigue or blurred vision.

Frequently Asked Questions

References

• United States Food and Drug Administration. Emrelis (Telisotuzumab Vedotin-tllv) Prescribing Information and Approval Summary.
• DrugBank Online Database. Telisotuzumab Vedotin Compound Summary (Accession Number DB15104).
• National Cancer Institute. Antibody-Drug Conjugates in Non-Small Cell Lung Cancer Management.

Legal Disclaimer

The information provided is for educational and informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider at any hospital or any local clinic before starting or stopping any medication.